Analyst outperform ratings on Crispr stocks.

nadzry (25)in #crispr • 7 years ago

Cowen, Barclays and ROTH all host healthcare conferences next week;

• Intellia Therapeutics (NASDAQ:NTLA) initiated with Outperform rating and $76 (158% upside) price target at JMP Securities.

• CRISPR Therapeutics (NASDAQ:CRSP) initiated with Outperform rating and $69 (34% upside) price target at JMP.

With this, I’ll likely hold my Crispr theme options (EDIT and NTLA) for a medium/long term instead.

7 years ago in #crispr by nadzry (25)

$0.00